{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:36Z","timestamp":1786986936937,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clml.2021.06.014","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:56:33Z","timestamp":1624521393000},"page":"e832-e838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Risk of Non-Hodgkin's Lymphoma in HCV Patients in the United States Between 2013 and 2020: A Population-Based Study"],"prefix":"10.1016","volume":"21","author":[{"given":"Akram","family":"Alkrekshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2021.06.014_bib0001","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1473-3099(16)30325-5","article-title":"Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013","volume":"16","author":"Degenhardt","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"March","key":"10.1016\/j.clml.2021.06.014_bib0002","article-title":"Hepatitis C virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.clml.2021.06.014_bib0003","unstructured":"Hepatitis C. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c Accessed June 3, 2020."},{"issue":"8","key":"10.1016\/j.clml.2021.06.014_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.6371","article-title":"Prevalence of hepatitis C virus infection in US states and the District of Columbia, 2013 to 2016","volume":"1","author":"Rosenberg","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.clml.2021.06.014_bib0005","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1001\/jama.2019.20788","article-title":"Screening for hepatitis C virus infection in adolescents and adults: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"323","author":"Chou","year":"2020","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.clml.2021.06.014_bib0006","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.014_bib0007","doi-asserted-by":"crossref","unstructured":"Hartge P., Smith M.T. Environmental and behavioral factors and the risk of non-Hodgkin lymphoma. In: Cancer Epidemiology Biomarkers and Prevention. Vol 16. American Association for Cancer Research; 2007:367\u2013368. doi:10.1158\/1055-9965.EPI-07-0031","DOI":"10.1158\/1055-9965.EPI-07-0031"},{"issue":"6","key":"10.1016\/j.clml.2021.06.014_bib0008","first-page":"677","article-title":"Obesity and risk of non-Hodgkin lymphoma (United States)","volume":"18","author":"Chiu","year":"2007","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.clml.2021.06.014_bib0009","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1016\/j.respe.2018.05.180","article-title":"Risk of pancreatic cancer and non-Hodgkin lymphoma associated with healthy lifestyle behaviors in the EPIC study","volume":"66","author":"Naudin","year":"2018","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"1","key":"10.1016\/j.clml.2021.06.014_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3414-2","article-title":"The dose-response relationship between tobacco smoking and the risk of lymphomas: a case-control study","volume":"17","author":"Taborelli","year":"2017","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.clml.2021.06.014_bib0011","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/1040841X.2020.1760786","article-title":"Bacterial infection and non-Hodgkin's lymphoma","volume":"46","author":"Melenotte","year":"2020","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.clml.2021.06.014_bib0012","unstructured":"U.S. Department of Health. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999-2016): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institu. 2019. http:\/\/www.cdc.gov\/cancer\/dataviz%0Ahttps:\/\/gis.cdc.gov\/Cancer\/USCS\/DataViz.html"},{"issue":"1","key":"10.1016\/j.clml.2021.06.014_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens5010018","article-title":"The role of gammaherpesviruses in cancer pathogenesis","volume":"5","author":"Jha","year":"2016","journal-title":"Pathogens"},{"issue":"2\u20133","key":"10.1016\/j.clml.2021.06.014_bib0014","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12026-014-8490-7","article-title":"Function of the tetraspanin molecule CD81 in B and T cells","volume":"58","author":"Levy","year":"2014","journal-title":"Immunol Res"},{"issue":"6","key":"10.1016\/j.clml.2021.06.014_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0156384","article-title":"In situ hepatitis C NS3 protein detection is associated with high grade features in hepatitis C-associated B-cell non-hodgkin lymphomas","volume":"11","author":"Canioni","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.clml.2021.06.014_bib0016","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10238-020-00615-6","article-title":"HCV infection and non-Hodgkin lymphomas: an evolving story","volume":"20","author":"Defrancesco","year":"2020","journal-title":"Clin Exp Med"},{"issue":"7","key":"10.1016\/j.clml.2021.06.014_bib0017","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jvh.12518","article-title":"The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis","volume":"23","author":"Peveling-Oberhag","year":"2016","journal-title":"J Viral Hepat"},{"issue":"6","key":"10.1016\/j.clml.2021.06.014_bib0018","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1053\/j.gastro.2003.09.025","article-title":"Prevalence of hepatitis C virus infection in B-cell Non-Hodgkin's lymphoma: systematic, review and meta-analysis","volume":"125","author":"Gisbert","year":"2003","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.clml.2021.06.014_bib0019","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1349-7006.2004.tb03256.x","article-title":"Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies","volume":"95","author":"Matsuo","year":"2004","journal-title":"Cancer Sci"},{"issue":"11","key":"10.1016\/j.clml.2021.06.014_bib0020","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-06-0308","article-title":"Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies","volume":"15","author":"Dal Maso","year":"2006","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"10.1016\/j.clml.2021.06.014_bib0021","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cgh.2008.02.011","article-title":"Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium","volume":"6","author":"De Sanjose","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clml.2021.06.014_bib0022","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.29642","article-title":"Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: no longer a difficult-to-treat population","volume":"67","author":"Sikavi","year":"2018","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.clml.2021.06.014_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v10100545","article-title":"Epidemiology and elimination of HCV-related liver disease","volume":"10","author":"Pradat","year":"2018","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.clml.2021.06.014_bib0024","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2017","journal-title":"Lancet HIV"},{"issue":"18","key":"10.1016\/j.clml.2021.06.014_bib0025","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.297.18.2010","article-title":"Lymphoproliferative precursor diseases in US Veterans with hepatitis C virus","volume":"297","author":"Giordano","year":"2010","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clml.2021.06.014_bib0026","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ijc.20021","article-title":"Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study","volume":"111","author":"Engels","year":"2004","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.clml.2021.06.014_bib0027","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2021.06.014_bib0028","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<237::AID-IJC12>3.0.CO;2-I","article-title":"Risk of non-Hodgkin's lymphoma in patients with hepatitis C virus infection","volume":"80","author":"Ohsawa","year":"1999","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.clml.2021.06.014_bib0029","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1182\/blood-2002-01-0226","article-title":"Prospective study of hepatitis C viral infection as a risk factor for subsequent B-cell neoplasia","volume":"99","author":"Rabkin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.014_bib0030","series-title":"Who Global Hepatitis Report","first-page":"83","year":"2017"},{"issue":"11","key":"10.1016\/j.clml.2021.06.014_bib0031","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/jvh.12173","article-title":"The new paradigm of hepatitis C therapy: integration of oral therapies into best practices","volume":"20","author":"Afdhal","year":"2013","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.clml.2021.06.014_bib0032","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/01.qai.0000131932.21612.49","article-title":"Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection","volume":"37","author":"Fishbein","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.clml.2021.06.014_bib0033","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14218\/JCTH.2016.00011","article-title":"Accessibility to oral antiviral therapy for patients with chronic hepatitis c in the united states","volume":"4","author":"Saab","year":"2016","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10.1016\/j.clml.2021.06.014_bib0034","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canep.2014.12.001","article-title":"Racial differences in three major NHL subtypes: descriptive epidemiology","volume":"39","author":"Li","year":"2015","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.clml.2021.06.014_bib0035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/gut.2006.099150","article-title":"Rate and predictors of treatment prescription for hepatitis C","volume":"56","author":"Butt","year":"2007","journal-title":"Gut."},{"issue":"5","key":"10.1016\/j.clml.2021.06.014_bib0036","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2105\/AJPH.2007.113225","article-title":"Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study","volume":"98","author":"Rousseau","year":"2008","journal-title":"Am J Public Health"},{"issue":"2","key":"10.1016\/j.clml.2021.06.014_bib0037","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/pds.1146","article-title":"Comparison of characteristics of treated and non-treated patients with Hepatitis C infection","volume":"15","author":"Hare","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.clml.2021.06.014_bib0038","doi-asserted-by":"crossref","first-page":"530","DOI":"10.5604\/01.3001.0010.0282","article-title":"Racial disparities in hepatitis c treatment eligibility","volume":"16","author":"Sims","year":"2017","journal-title":"Ann Hepatol"},{"issue":"12","key":"10.1016\/j.clml.2021.06.014_bib0039","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/sj.leu.2400869","article-title":"The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma","volume":"11","author":"Silvestri","year":"1997","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2021.06.014_bib40","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjmed.2007.06.022","article-title":"Viral Elimination Reduces Incidence of Malignant Lymphoma in Patients with Hepatitis C","volume":"120","author":"Kawamura","year":"2007","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.clml.2021.06.014_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canep.2014.12.001","article-title":"Racial differences in three major NHL subtypes: Descriptive epidemiology","volume":"39","author":"Li","year":"2015","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.clml.2021.06.014_bib42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/gut.2006.099150","article-title":"Rate and predictors of treatment prescription for hepatitis C","volume":"56","author":"Butt","year":"2007","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.clml.2021.06.014_bib43","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2105\/AJPH.2007.113225","article-title":"Racial differences in the evaluation and treatment of hepatitis C among veterans: A retrospective cohort study","volume":"98","author":"Rousseau","year":"2008","journal-title":"Am J Public Health"},{"issue":"2","key":"10.1016\/j.clml.2021.06.014_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/pds.1146","article-title":"Comparison of characteristics of treated and non-treated patients with Hepatitis C infection","volume":"15","author":"Hare","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.clml.2021.06.014_bib45","doi-asserted-by":"crossref","first-page":"530","DOI":"10.5604\/01.3001.0010.0282","article-title":"Racial disparities in hepatitis c treatment eligibility","volume":"16","author":"Sims","year":"2017","journal-title":"Ann Hepatol"},{"issue":"12","key":"10.1016\/j.clml.2021.06.014_bib46","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/sj.leu.2400869","article-title":"The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin\u2019s lymphoma","volume":"11","author":"Silvestri","year":"1997","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:39:23Z","timestamp":1761871163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021002445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2152265021002445"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.06.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Non-Hodgkin's Lymphoma in HCV Patients in the United States Between 2013 and 2020: A Population-Based Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}